الفهرس | Only 14 pages are availabe for public view |
Abstract The use of niosomal carrier system will improve natamycin (NAT) ocular bioavailability. So this study was aimed to develop dual-purpose NAT-loaded niosomes in ketorolac tromethamine (KT) gels ocular drug delivery system to improve the clinical efficacy of natamycin through enhancing its penetration through corneal tissue and reducing inflammation associated with fungal keratitis (FK). Niosomes were prepared using the reverse-phase evaporation technique. In vitro experimental and in vivo clinical evaluations for these formulations were done for assessment of their safety and efficacy for treatment of Candida albicans and Aspergillus flavus Keratitis in Rabbits. In vitro release study was carried out by dialysis method. In vivo microbiological and histopathological studies were performed on albino rabbits.NAT niosomes exhibited high entrapment efficiency percentage (E.E%) were ranged between 90.99% (F3) and 97.64% (F8) and particle size diameter ranging from 181.75 ± 0.64 to 498.95 ± 0.64 nm, with negatively charged zeta potential (ZP) ranging between -28.80 mV and -73.75 mV.NAT niosomal dispersion exhibited prolonged in vitro drug % release efficiency were ranged between (19.86% (F15) to 61.1% (F6) over 24h) |